K. Mohorcic

Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity

C. Pirker, W. Berger, W. Klepetko, 2019, Cells.

Expansion of pulmonary CD8+CD56+ natural killer T-cells in hypersensitivity pneumonitis.

P. Korošec, M. Košnik, I. Kern, 2007, Chest.

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

A. Valipour, A. Addeo, T. Čufer, 2022, Therapeutic Advances in Medical Oncology.

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

N. Reinmuth, U. Dafni, R. Stahel, 2020 .

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study

W. Berger, W. Klepetko, T. Čufer, 2021, Translational lung cancer research.